Stock Information

• Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus
  Fri, May 8, 2026 4:47 PM
• Earnings Beat: Neurocrine Biosciences, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
  Fri, May 8, 2026 12:46 PM
• Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why
  Thu, May 7, 2026 4:45 PM
• Truist Securities Maintains Buy on Neurocrine Biosciences, Raises Price Target to $155
  Thu, May 7, 2026 11:43 AM
• Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside
  Wed, May 6, 2026 6:24 PM
• Is Neurocrine Biosciences (NBIX) Pricing In Too Much Caution After Recent Share Gains?
  Wed, May 6, 2026 3:21 PM
• Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $246
  Wed, May 6, 2026 2:35 PM
• Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $191
  Wed, May 6, 2026 2:06 PM
• Neurocrine Biosciences, Inc. Q1 2026 Earnings Call Summary
  Wed, May 6, 2026 12:30 PM
• Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
  Wed, May 6, 2026 12:30 PM

Financial data not available